Extracellular vesicles for acute kidney injury in preclinical rodent models: a meta-analysis
Liu C., Wang J., Hu J., Fu B., Mao Z., Zhang H.
Meta-analysis with a reported sample of 552 on Acute Kidney Injury, Chronic Inflammation, published in Stem Cell Res Ther (2020) — summary generated from the PubMed abstract.
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Meta-analysis
- Journal
- Stem Cell Res Ther (2020)
- Reported sample size
- 552
- Source database
- Europe PMC
- PMID
- 31900218
- PMCID
- PMC6942291
- DOI
- 10.1186/s13287-019-1530-4
- Citations
- 35
Abstract (original English)
Introduction Extracellular vesicles (EVs), especially stem cell-derived EVs, have emerged as a potential novel therapy for acute kidney injury (AKI). However, their effects remain incompletely understood. Therefore, we performed this meta-analysis to systematically review the efficacy of EVs on AKI in preclinical rodent models. Methods We searched PubMed, EMBASE, and the Web of Science up to March 2019 to identify studies that reported the treatment effects of EVs in a rodent AKI model. The primary outcome was serum creatinine (Scr) levels. The secondary outcomes were the blood urea nitrogen (BUN) levels, renal injury score, percentage of apoptotic cells, and interleukin (IL)-10 and tumour necrosis factor (TNF)-α levels. Two authors independently screened articles based on the inclusion and exclusion criteria. The meta-analysis was conducted using RevMan 5.3 and R software. Results Thirty-one studies (n = 552) satisfied the inclusion criteria. Pooled analyses demonstrated that the levels of Scr (SMD = - 3.71; 95% CI = - 4.32, - 3.10; P Conclusion The present meta-analysis confirmed that EV therapy could improve renal function and the inflammatory response status and reduce cell apoptosis in a preclinical rodent AKI model. This provides important clues for human clinical trials on EVs.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Worldwide hotspots and trends in stem cell therapy for kidney disease in the last decade: a bibliometric and visualization analysis from 2015 to 2024
Systematic Review on Chronic Kidney Disease, Acute Kidney Injury, published in Front Immunol (2025) — summary generated from the PubMed abstract.
- 2025
Front Immunol2 citations - Level AMeta-analysisEurope PMC
Protective role of exosomes in renal ischemia-reperfusion injury: a systematic review and meta-analysis
Meta-analysis on Chronic Kidney Disease, Acute Kidney Injury, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.
- 2025
Front Pharmacol1 citations - Level AMeta-analysisEurope PMC
Extracellular vesicles for ischemia/reperfusion injury-induced acute kidney injury: a systematic review and meta-analysis of data from animal models
Meta-analysis on Acute Kidney Injury, published in Syst Rev (2022) — summary generated from the PubMed abstract.
- 2022
Syst Rev8 citations - Level AMeta-analysisPubMed
Concise Review: Using Fat to Fight Disease: A Systematic Review of Nonhomologous Adipose-Derived Stromal/Stem Cell Therapies.
Meta-analysis on Osteoarthritis, Acute Kidney Injury, Cardiovascular Disease, Stroke Research, published in Stem Cells (2018) — summary generated from the PubMed abstract.
- 2018
Stem Cells101 citations - Level AMeta-analysisEurope PMC
Extracellular vesicles derived from mesenchymal stromal cells may possess increased therapeutic potential for acute kidney injury compared with conditioned medium in rodent models: A meta-analysis
Meta-analysis on Chronic Kidney Disease, Acute Kidney Injury, published in Exp Ther Med (2016) — summary generated from the PubMed abstract.
- 2016
Exp Ther Med17 citations - Level BClinical TrialEurope PMC
Beyond preclinical promise: can mesenchymal stromal cell-derived extracellular vesicles reliably target tubular epithelial cells?
Clinical Trial on Chronic Kidney Disease, Acute Kidney Injury, published in Extracell Vesicles Circ Nucl Acids (2025) — summary generated from the PubMed abstract.
- 2025
Extracell Vesicles Circ Nucl Acids